Can a common gout pill protect heart bypass patients?
NCT ID NCT07287345
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether the anti-inflammatory drug colchicine can lower inflammation and reduce the risk of atrial fibrillation (an irregular heartbeat) after coronary artery bypass surgery. 24 adults scheduled for bypass surgery will be randomly assigned to receive either colchicine or a placebo, starting 5 days before surgery and continuing for 10 days after. Researchers will measure inflammatory markers and track who develops atrial fibrillation, aiming to gather data for a larger future trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent a common complication of heart bypass surgery.
What could go wrong
This is a very small pilot study with only 24 participants, so results may not apply to everyone. Colchicine can cause side effects like stomach upset or, rarely, more serious issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Kentucy
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••